ArticleFrontiers in pharmacology2025
Balanophora polysaccharide improves renal injury and fibrosis in db/db diabetic nephropathy mice via NLRP3 inflammasome mediated inflammation.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The ELAVL1-PLAUR-suPAR Axis Exacerbates Diabetic Nephropathy by Promoting Podocyte Injury and Inflammation.Journal of diabetes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetic nephropathy (DN) is a major complication of diabetes, with renal fibrosis leading to progressive renal function decline. Understanding interventions for renal injury and fibrosis in DN is vital, and given its complex pathogenesis, new therapeutic agents are urgently needed. Methods: The DN model was established using db/db mice, which received balanophora polysaccharide (BPS) treatment. The therapeutic efficacy of BPS for DN was evaluated by measuring body weight, fasting blood glucose (FBG), lipid profiles, renal function parameters, serum inflammatory factors, and histopathological changes. Furthermore, the underlying mechanisms by which BPS exerted its therapeutic effects were investigated using transmission electron microscopy (TEM), immunohistochemistry (IHC), immunofluorescence (IF), and Western blotting. Results: BPS significantly reduced body weight, as well as fasting blood glucose (FBG) and lipid levels in db/db mice. Additionally, it improved renal function and effectively alleviated renal injury. Moreover, BPS decreased the expression of extracellular matrix (ECM) proteins and inhibited ECM deposition, thereby alleviating the progression of renal fibrosis in DN and reducing cell apoptosis. Notably, BPS effectively inhibited the activity of NLRP3 inflammasome in the renal tissue of db/db mice, which in turn mitigated renal inflammatory response and fibrosis. Conclusion: BPS can improve renal injury and renal fibrosis in db/db diabetic nephropathy mice, which may be related to the decrease of apoptosis, inhibition of inflammation, reduction of ECM, and regulation of NLRP3 inflammasome. This study provides a scientific basis for the clinical application of BPS in the treatment of renal fibrosis in DN and is expected to promote the drug development and clinical application of BPS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.